Takeda boosts sales of Lundbeck-developed drug in H1 2021
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13409738.ece/ALTERNATES/schema-16_9/20237458598092-1920x1080we.jpg)
In the months spanning April to September, which make up the first half of the staggered fiscal year of 2021, Takeda's revenue has gone up by 12.8 percent compared to the prior Covid-19-affected year, it reports in a press release on Thursday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Takeda's new CEO in Denmark wants to hire more people
For subscribers